Support for a hybrid application in the European Union

Marketing Communication
Regulatory affairs Pharmaceutical industry
Regulatory affairs Pharmaceutical industry
June 29, 2021
  • Drug Registration
image_pdfPDF

BlueReg was involved in the review of a Hybrid Application for a medicinal product in Ophthalmology to be submitted to the European Medicines Agency (EMA).

BlueReg reviewed the Module 3 (Quality) as well as the Quality Overall Summary (QOS), Non-Clinical Overview and Clinical Overview, to determine if they contained sufficient relevant evidence to support a Hybrid Application. BlueReg also reviewed the legal basis for validation of the Hybrid Application status in Module 1 of the dossier.

Register to download the Case study

    By sending this form, I agree that my personal data will be saved and processed according to data protection regulations and will be used only for commercial and marketing purposes only.

    Learn more

    BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: GDPR data request

    GDPR data request

    Thank you for your interest in BlueReg

    The file will be sent to you by email.

    Download your Case study